Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P08173

UPID:
ACM4_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P08173; B2RPP4; Q0VD60; Q4VBK7

BACKGROUND:
Muscarinic acetylcholine receptor M4, with the unique identifier P08173, is integral to the modulation of key cellular processes. It inhibits adenylate cyclase, affects phosphoinositide breakdown, and alters potassium channel activity via G protein interaction. This receptor's action is fundamental in transmitting cholinergic signals, influencing numerous physiological pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the Muscarinic acetylcholine receptor M4's function offers a promising avenue for developing novel therapeutic approaches. Given its central role in cholinergic signaling, targeting this receptor could lead to breakthroughs in treating diseases where cholinergic systems are implicated.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.